Clorox says no to Icahn’s $10.2 billion buyout offer

NEW YORK – Clorox Co. is turning down billionaire investor Carl Icahn’s offer to buy the company, saying the price of $76.50 per share is too low.

The Oakland, Calif., company also said Monday that it is adopting a “poison pill” shareholder rights measure to ward off the bid from Icahn, who is the largest shareholder in Clorox. The company said it is committed to its current strategy, saying its own plans are the best way to create value for its shareholders.

On Friday, Icahn Enterprises LP offered to buy Clorox for $10.2 billion in cash. Rather than urge the company to take the unsolicited offer, Icahn said Clorox should shop itself to competitors, saying it could get a better offer.

The stockholder rights plan will take effect if a person or group acquires a 10-percent stake in Clorox in a transaction not approved by the board. If that happens, the company will issue one stock purchase right for each share outstanding on July 28. Icahn bought a 9.4-percent stake in Clorox in December.

Associated Press

Thank you for visiting Spokesman.com. To continue reading this story and enjoying our local journalism please subscribe or log in.

You have reached your article limit for this month.

Subscribe now and enjoy unlimited digital access to Spokesman.com

Unlimited Digital Access

Stay connected to Spokane for as little as 99¢!

Subscribe for access

Already a Spokesman-Review subscriber? Activate or Log in

You have reached your article limit for this month.

Subscribe now and enjoy unlimited digital access to Spokesman.com

Unlimited Digital Access

Stay connected to Spokane for as little as 99¢!

Subscribe for access

Already a Spokesman-Review subscriber? Activate or Log in

Oops, it appears there has been a technical problem. To access this content as intended, please try reloading the page or returning at a later time. Already a Spokesman-Review subscriber? Activate or Log in